Efficacy of CHDF Using AN69ST Membrane in Severe Sepsis

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K18313
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55060:Emergency medicine-related
• Research Institution: Gunma University
• Principal Investigator: Otaka Maiko 群馬大学, 医学部附属病院, 助教 (30816327)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: 敗血症性ショック / AN69ST膜 / 持続血液ろ過透析

Outline of Final Research Achievements

A CHDF membrane for septic shock has been launched. In order to appeal as a sepsis treatment originating in Japan, even higher quality evidence is essential, and research at other institutions is necessary.
However, due to the global COVID-19 pandemic for three years, the movement of people has been restricted, and the research at other facilities became difficult. It was difficult to secure beds for other diseases to treat patients with severe COVID-19. As a result, we ended up falling far behind the original schedule.
In the past 1-2 years, the situation has returned to normal, and although the Grant-in-Aid for Scientific Research for this research ended last year, we would like to continue collecting data in the future.

Free Research Field

麻酔・集中治療

Academic Significance and Societal Importance of the Research Achievements

敗血症治療の血液浄化療法に関してはnon-renal indicationで行われることは推奨されておらず、海外での研究もわずかである。海外ではCVVHが基本であるが、本邦においては浄化量に制限があるためCHDFで行うことが多い。本研究対象であったAN69ST膜は本邦発の敗血症性ショックの治療法であるため、エビデンスが蓄積されれば敗血症に対する新たな治療法として確立する可能性もある。引き続きデータ収集を行っていきたい。